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OBJECTIVES The goal of this study was to assess the interaction between heart failure (HF) etiology and
response to milrinone in decompensated HF.
BACKGROUND Etiology has prognostic and therapeutic implications in HF, but its relationship to response
to inotropic therapy is unknown.
METHODS The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic
Heart Failure (OPTIME-CHF) study randomized 949 patients with systolic dysfunction and
decompensated HF to receive 48 to 72 h of intravenous milrinone or placebo. The primary
end point was days hospitalized from cardiovascular causes within 60 days. In a post-hoc
analysis, we evaluated the interaction between response to milrinone and etiology of HF.
RESULTS The primary end point was 13.0 days for ischemic patients and 11.7 days for nonischemic
patients (p  0.2). Sixty-day mortality was 11.6% for the ischemic group and 7.5% for the
nonischemic group (p  0.03). After adjustment for baseline differences, there was a
significant interaction between etiology and the effect of milrinone. Milrinone-treated
patients with ischemic etiology tended to have worse outcomes than those treated with
placebo in terms of the primary end point (13.6 days for milrinone vs. 12.4 days for placebo,
p  0.055 for interaction) and the composite of death or rehospitalization (42% vs. 36% for
placebo, p 0.01 for interaction). In contrast, outcomes in nonischemic patients treated with
milrinone tended to be improved in terms of the primary end point (10.9 vs. 12.6 days
placebo) and the composite of death or rehospitalization (28% vs. 35% placebo).
CONCLUSIONS Milrinone may have a bidirectional effect based on etiology in decompensated HF. Milrinone
may be deleterious in ischemic HF, but neutral to beneficial in nonischemic
cardiomyopathy. (J Am Coll Cardiol 2003;41:997–1003) © 2003 by the American College
of Cardiology Foundation
Despite their similar presentations, ischemic and nonisch-
emic heart failure (HF) represent distinct diseases with
different pathophysiology, response to therapy, and progno-
sis. It is well-established that patients with ischemic HF
have worse long-term outcomes than patients with nonisch-
emic cardiomyopathy (1–4). Substantial heterogeneity in
outcomes also exists among patients with nonischemic HF,
with some etiologies having significantly better prognosis
than others (4).
The response to some chronic medical therapies may
differ between patients with ischemic and nonischemic
etiology of cardiomyopathy (5). The association between
etiology, outcomes, and response to acute therapies in the
setting of decompensated HF is unknown. Many potential
differences exist in the pathophysiology of HF exacerbations
between patients with ischemic and nonischemic etiology,
most notably the presence or absence of ischemia as a trigger
for decompensation. Positive inotropic agents, especially
adrenergic agonists such as dobutamine, may be associated
with increasing myocardial oxygen demand and the poten-
tial to induce myocardial ischemia or malignant arrhythmias
(6). Milrinone, a selective phosphodiesterase III inhibitor,
has little effect on myocardial oxygen demand and, there-
fore, may be better tolerated by patients with ischemic
cardiomyopathy (7). Additionally, inotropic stimulation
may accelerate HF progression in patients with ischemic
heart disease and chronically hibernating myocardium (8–
10). Patients with nonischemic HF, on the other hand, may
have better tolerance for the potential adverse effects of
inotropic therapy and, thus, a more favorable risk/benefit
ratio of this therapy. Whether these hypothetical consider-
ations impact the association between the efficacy of short-
term inotropic therapy and etiology during HF exacer-
bations is unknown. In a post-hoc analysis, we sought to
evaluate the hypothesis that HF etiology would impact
the response to intravenous milrinone in patients enrolled
in the Outcomes of a Prospective Trial of Intravenous
Milrinone for Exacerbations of Chronic Heart Failure
(OPTIME-CHF) study, a double-blind, randomized,
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placebo-controlled trial of milrinone during hospitalizations
for exacerbations of chronic HF.
METHODS
Study design. The study design and primary results of
OPTIME-CHF have been published elsewhere (11,12).
Briefly, the OPTIME-CHF study randomized 949 patients
with systolic dysfunction and exacerbations of HF to receive
48 to 72 h of intravenous milrinone therapy (0.5 g/kg/min
without a loading dose) or placebo in a double-blinded
fashion. Patients felt to require inotropic therapy and those
with evidence of active ischemia within the prior three
months, severe renal impairment (serum creatinine
3.0 mg/dl), severe hypotension (systolic blood pressure
80 mm Hg), or unstable arrhythmias were excluded.
Background therapy was left to the discretion of the treating
physician, but specific recommendations for optimal phar-
macotherapy based on current guidelines were included with
the study protocol. The primary study end point was days
hospitalized from cardiovascular causes within 60 days of
study drug infusion. For the purpose of the primary end
point, patients who died or were lost to follow-up were
considered as hospitalized for the remainder of the time up
to 60 days. Secondary end points were 60-day mortality, the
composite of death and rehospitalization, the ability to
reach target dosing of angiotensin-converting enzyme
(ACE) inhibitors, and quality of life (QOL); QOL was
assessed using a visual analog scale from 0 (worst) to 100
(best) and a subjective health status questionnaire assessing
activity limitations, symptoms, and/or emotions as better,
worse, or the same. The present analysis of the OPTIME-
CHF data was designed to evaluate the hypothesis that the
response to milrinone would differ between patients with
ischemic or nonischemic etiology of HF.
Classification of HF etiology. An underlying etiology of
HF (ischemic vs. nonischemic) was recorded at the time of
randomization based on clinical judgment of the treating
physician. In order to evaluate the robustness of our findings
in light of potential variability in the criteria used to classify
etiology, we also assessed two alternative definitions of
ischemic etiology. First, patients were included in the
ischemic group if they were classified as ischemic by the
enrolling investigator or if they had any history of coronary
artery bypass grafting (CABG), percutaneous coronary in-
tervention (PCI), or myocardial infarction (MI) (broad
definition). This reclassification resulted in 101 patients
being moved from the nonischemic group to the ischemic
group. Alternatively, patients were classified as ischemic
only if they had a history of CABG, PCI, or MI, regardless
of the enrolling investigator’s classification (narrow defini-
tion). This reclassification resulted in 41 patients being
reclassified into the nonischemic group.
Statistical analysis. Continuous variables are provided as
means  SD, and categorical variables are shown as
percentages. Comparisons between groups for continuous
variables were performed using Student t test or Wilcoxon
rank-sum test, as appropriate. Comparisons for categorical
variables were performed using the chi-squared test. A
multivariable Cox proportional hazards model was used to
adjust for differences between groups for both the primary
end point and 60-day mortality. Multivariable logistic
regression was used for the composite end point of death or
rehospitalization. To assess the possibility of a differential
effect of milrinone based on HF etiology, the etiology-
treatment interaction term was included in the final model
for each end point. This process was repeated for each of the
two alternative definitions of ischemic etiology.
RESULTS
Baseline characteristics. Four hundred eighty-five pa-
tients (51%) had ischemic HF, and 464 (49%) had non-
ischemic HF, based on the assessment of the enrolling
physician. Within the category of nonischemic HF, the
most common specific etiologies were idiopathic (38%) and
hypertensive (21%). There were multiple baseline differ-
ences between the ischemic and nonischemic groups, with
ischemic patients more likely to be older, white, male, and
diabetic than were nonischemic patients. Complete baseline
characteristics are shown in Table 1.
Outcomes by etiology. Study outcomes tended to be worse
in the ischemic group than in the nonischemic group (Table
2). The primary end point of days hospitalized for cardio-
vascular causes or death within 60 days after randomization
was 13.0  14.2 days for those with ischemic HF and
11.7  13.9 days for those with nonischemic HF (p  0.2).
Overall mortality tended to be greater in the ischemic group
than the nonischemic patients. Sixty-day mortality was
significantly greater for ischemic patients (11.6%) than for
nonischemic patients (7.5%, p  0.03). The combined end
point of death or rehospitalization at 60 days was 38.7% in
the ischemic patients and 31.5% in the nonischemic patients
(p  0.02).
Among other secondary end points, a significantly greater
percentage of patients with nonischemic HF was able to
reach target dosing of ACE inhibitors at hospital discharge
(49%) when compared with those with ischemic HF (36%,
p  0.001). Treatment failure while on the study drug was
similar between the two groups (14.2% for ischemic patients
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CABG  coronary artery bypass grafting
HF  heart failure
MI  myocardial infarction
OPTIME-CHF  Outcomes of a Prospective Trial of
Intravenous Milrinone for
Exacerbations of Chronic Heart
Failure study
PCI  percutaneous coronary intervention
QOL  quality of life
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vs. 15.2% for nonischemic patients, p 0.7). In general, the
incidence of in-hospital complications did not differ be-
tween the etiologic groups (13.2% for ischemic patients vs.
13.0% for nonischemic patients). Notably, despite the worse
overall prognosis in ischemic patients, the incidence of atrial
or ventricular arrhythmias did not differ significantly be-
tween the groups. The incidence of new atrial fibrillation or
flutter during the index hospitalization was 2.7% for the
ischemic group and 3.4% for the nonischemic group (p 
0.49). Sustained ventricular tachycardia occurred in 1.6% of
ischemic patients and 2.4% of nonischemic patients (p 
0.42), with ventricular fibrillation occurring in 0.6% and
1.7%, respectively (p  0.11). The most common in-
hospital adverse event was sustained hypotension necessi-
tating treatment, which did not differ in incidence between
etiologic groups (7.0% for ischemic patients vs. 6.9% for
nonischemic patients, p  0.9).
Baseline QOL data did not differ significantly between
the ischemic and nonischemic groups. Visual analog scale
rating of QOL was 42  22 for the ischemic group and 41
 22 for the nonischemic group (p 0.5). Both groups had
substantial improvement over baseline in visual analog
QOL by hospital discharge (mean improvement of 29 for
both groups, p  0.4), which lessened by 60 days follow-up
(mean improvement of 23 for ischemic patients vs. 25 for
nonischemic patients, p  0.2). There was a nonsignificant
trend towards improved QOL by the subjective health
status questionnaire in the nonischemic group compared
with the ischemic group (p  0.053 at 60 days) (Table 2).
Effect of milrinone treatment. To evaluate the hypothesis
that the response to milrinone therapy would differ based on
HF etiology, etiology-treatment interaction terms were
included in the multivariable model for each end point.
After multivariable adjustment for baseline differences,
there was an interaction identified between treatment as-
signment (milrinone vs. placebo) and HF etiology (Table 3).
This was most pronounced for the composite end point of
death or rehospitalization (p  0.01). Similar trends were
identified for other end points but reached nominal statis-
tical significance only for in-hospital mortality (p  0.04).
Kaplan-Meier survival curves by etiology and treatment
assignment are shown in Figure 1.
Table 1. Baseline Characteristics by Heart Failure Etiology
Ischemic
(n  485)
Nonischemic
(n  464) p Value
Randomized to milrinone 242 (50%) 235 (51%)
Age 70  11 61  16 0.0001
Gender
Male 341 (70%) 286 (62%) 0.005
Female 144 (30%) 178 (38%)
Race
White 391 (81%) 222 (48%) 0.001
Black 80 (17%) 230 (49%)
Other 14 (3%) 12 (3%)
History of arrhythmia 262 (54%) 195 (42%) 0.001
Hospitalizations prior 12 months 2.1  2.1 1.9  2.1 0.06
NYHA functional class
I 1 (0.2%) 0 (0%) 0.2
II 31 (6%) 33 (7%)
III 208 (43%) 223 (48%)
IV 242 (50%) 205 (45%)
JVP  6 313 (70%) 323 (76%) 0.05
Rales 405 (84%) 366 (79%) 0.07
S3 263 (55%) 285 (63%) 0.02
MR murmur 225 (48%) 216 (49%) 0.9
Heart rate 82  15 87  16 0.0001
Systolic blood pressure 120  18 120  18 0.8
Diastolic blood pressure 70  12 73  13 0.0001
Ejection fraction (%) 25  8 22  8 0.0001
Diabetes mellitus 240 (50%) 178 (38%) 0.0001
In-hospital dobutamine treatment 53 (11%) 46 (10%) 0.6
ACE inhibitor on admission 329 (68%) 336 (73%) 0.1
Beta-blocker on admission 120 (25%) 92 (20%) 0.07
Amiodarone on admission 82 (17%) 65 (14%) 0.2
Digoxin on admission 336 (69%) 356 (77%) 0.01
Serum sodium 138  4 138  4 0.1
Serum potassium 4.2  0.6 4.2  1.6 0.5
Serum creatinine 1.5  0.5 1.4  0.5 0.001
Visual analog QOL score (0–100) 42  22 41  22 0.5
ACE angiotensin-converting enzyme; JVP jugular venous pressure; MRmitral regurgitation; NYHANew York Heart
Association; QOL  quality of life; S3  third heart sound.
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In patients with ischemic HF, milrinone treatment
tended to be associated with prolonged hospitalization and
higher mortality. Among ischemic patients, the primary end
point of days hospitalized or death within 60 days was 13.6
for milrinone versus 12.4 for placebo (p  0.055 for
etiology-treatment interaction). The composite of death or
rehospitalization at 60 days was 42% for ischemic patients
treated with milrinone and 36% for those treated with
placebo (p  0.01 for etiology-treatment interaction) (Fig.
2). In-hospital mortality for milrinone-treated patients with
ischemic HF was 5.0% versus 1.6% for placebo (p  0.04
for etiology-treatment interaction), and 60-day mortality
was 13.3% for milrinone versus 10.0% for placebo (p 0.21
for etiology-treatment interaction).
In contrast, patients with nonischemic HF demonstrated
evidence of benefit with milrinone therapy compared with
placebo. The primary end point in the milrinone-treated
nonischemic patients was 10.9 days versus 12.6 days for
placebo (p  0.055 for etiology-treatment interaction). The
composite of death or rehospitalization at 60 days was 28%
for nonischemic patients treated with milrinone versus 35%
for those treated with placebo (p  0.01 for etiology-
treatment interaction) (Fig. 2). In-hospital mortality was
2.6% for milrinone versus 3.1% for placebo (p  0.04 for
etiology treatment interaction), with similar results at 60
days (7.3% vs. 7.7%, p  0.21 for etiology-treatment
interaction) (Fig. 2).
Because clinical outcomes after discharge (such as the rate
of rehospitalization) were crucial to the end points of
interest, we compared discharge medications for each of the
treatment-etiology groups (Table 4). Only digoxin was
significantly different between groups, with nonischemic
patients more likely to receive digoxin at hospital discharge.
Impact of etiology classification. In order to assess the
sensitivity of our findings to changes in our assumptions,
multivariable analyses were repeated using two alternative
definitions of ischemic etiology as previously defined. Re-
analysis of the data using the “broad definition” showed
small changes in the p values for the milrinone-etiology
interaction terms (from 0.055 to 0.12 for the primary end
point, from 0.011 to 0.015 for the composite of death or
rehospitalization, and from 0.21 to 0.28 for 60-day survival).
Alternatively, data were analyzed using the “narrow defini-
tion” of ischemic etiology. As in the first alternative analysis,
Table 2. Outcomes by Heart Failure Etiology
Ischemic
(n  485)
Nonischemic
(n  464) p Value
Primary end point (days) 13.0  14.2 11.7  13.9 0.2
Mortality
In-hospital 3.3% 2.8% 0.7
60 days 11.6% 7.5% 0.03
Death or rehospitalization at 60 days 38.7% 31.5% 0.02
Treatment failures (during infusion) 14.2% 15.2% 0.7
In-hospital complications (any) 13.2% 13.0% 0.9
Hypotension 7.0% 6.9% 0.9
New atrial fibrillation/flutter 2.7% 3.4% 0.5
Sustained ventricular tachycardia 1.6% 2.4% 0.4
Ventricular fibrillation 0.6% 1.7% 0.1
Reached target ACE dosing 36.0% 49.1% 0.001
Quality of life
Visual analog scale (0–100)
Baseline 42  22 41  22 0.5
 at hospital D/C 29  24 29  22 0.4
 at 30 days 20  28 24  26 0.06
 at 60 days 23  29 25  29 0.2
Subjective Health Questionnaire
(% better/same or worse)
 at hospital discharge 89/11 92/8 0.2
 at 30 days 59/41 66/34 0.1
 at 60 days 51/49 59/41 0.053
ACE  angiotensin-converting enzyme; D/C  discharge.
Table 3. Outcomes by Heart Failure Etiology and Treatment Assignment
Ischemic Nonischemic
p Value*Milrinone Placebo Milrinone Placebo
Days hospitalized at 60 days 13.6  15.5 12.4  12.7 10.9  12.4 12.6  15.3 0.055
In-hospital mortality 5.0% 1.6% 2.6% 3.1% 0.04
60-day mortality 13.3% 10.0% 7.3% 7.7% 0.21
Death  rehospitalization 42% 36% 28% 35% 0.02
*p value for the etiology treatment interaction term in the multivariable model.
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this resulted in small changes in the interaction term p
values (from 0.055 to 0.22 for the primary end point, from
0.011 to 0.015 for the death  rehospitalization composite,
and from 0.21 to 0.12 for 60-day survival). Notably, in all
three cases, the p values of the interaction term for the death
 rehospitalization end point remained statistically signif-
icant.
DISCUSSION
Exacerbations of HF represent a major component of health
care costs, resulting in hospitalizations, emergency depart-
ment utilization, and unscheduled clinic visits (13). Al-
though 75% of HF costs are related to hospitalizations for
decompensated HF (13), the majority of randomized trials
in HF have addressed chronic treatment strategies, and
relatively little is known about the optimal management of
hospitalized patients (14–18). Additionally, although the
chronic oral administration of positive inotropic agents has
been shown to increase mortality in patients with left
ventricular dysfunction (19–22), their efficacy as short-term
treatments for HF exacerbations has not been well studied.
The OPTIME-CHF study is the first trial to systematically
evaluate a strategy of short-term inotrope use during exac-
erbations of chronic HF , and the current study is the first
to evaluate a potential interaction between HF etiology,
treatment, and outcomes in such patients.
Substantial heterogeneity exists among patients with HF
in terms of both outcomes and response to specific thera-
pies. The last several decades have seen a shift in the
etiologic basis of HF away from hypertension and valvular
disease towards ischemic heart disease, which now com-
prises about 70% of all HF from systolic dysfunction in
clinical trials (23). The underlying etiology of HF is among
the most important determinants of prognosis in patients
with chronic HF, and an ischemic etiology of cardiomyop-
athy has been shown to be associated with worsened
Figure 1. Kaplan-Meier survival curves to 60 days by heart failure etiology and treatment assignment.
Figure 2. Composite end point of death  rehospitalization by heart
failure etiology and treatment assignment. p  0.01 for etiology-treatment
interaction.
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long-term prognosis (3,4). The current study extends this
finding to the setting of HF decompensations, demonstrat-
ing worsened short- and intermediate-term outcomes in
patients with ischemic HF when compared with those with
nonischemic cardiomyopathy. Mortality at 60 days was
significantly higher in ischemic patients compared with
nonischemic, and other measured study outcomes also
tended to be worse in the ischemic group.
Milrinone-etiology interaction. This study identified a
significant interaction between HF etiology and treatment
with milrinone. In patients with ischemic HF, milrinone
use was associated with prolonged or recurrent hospitaliza-
tion and a trend towards increased mortality. Several po-
tential explanations exist for this finding. Patients with
ischemic HF may have been more susceptible to malignant
arrhythmias than those with nonischemic cardiomyopathy
due to greater potential for re-entry around areas of myo-
cardial scar, a risk that could potentially be exacerbated by
treatment with milrinone. The current study does not
appear to support this explanation, however, as the in-
hospital incidence of sustained ventricular tachycardia or
ventricular fibrillation was actually greater in the nonisch-
emic patients treated with milrinone (5.9%) than in the
ischemic patients treated with milrinone (2.9%).
Another potential mechanism of adverse outcomes in
ischemic patients treated with milrinone could be the
presence of hibernating myocardium. Although the
OPTIME-CHF study excluded patients with clinical evi-
dence of ischemia, patients with ischemic HF may have
chronically ischemic hibernating myocardium in the absence
of overt ischemia (24). Data using positron emission tomog-
raphy scanning suggest that up to 50% of patients with
systolic dysfunction and ischemic heart disease may have
demonstrable myocardial hibernation (25). While treatment
with inotropic agents may increase contractility and cardiac
performance in patients with hibernating myocardium (the
mechanism for the utility of dobutamine echocardiography
in assessing myocardial viability), this may come at the
expense of the acceleration of apoptosis and underlying HF
progression (8,10,26). Whether short-term treatment with
milrinone (48 to 72 h) may have resulted in acceleration of
HF progression in patients with ischemic HF and hiber-
nating myocardium is unknown.
In contrast with patients with ischemic HF, the use of
milrinone appeared to have a neutral to beneficial impact on
outcomes in patients with nonischemic cardiomyopathy,
with less hospitalization and trends towards decreased
mortality with milrinone therapy in this subgroup. A similar
pattern of drug efficacy (more effective in nonischemic HF)
has been suggested for other pharmacologic agents, most
notably amiodarone (27,28). These data suggest the hy-
pothesis that milrinone may have a bi-directional effect in
decompensated HF based on etiology. This hypothesis
would need to be confirmed prospectively before being
incorporated into clinical practice.
Classification of etiology. The classification of patients
into ischemic or nonischemic categories in the OPTIME-
CHF study was done based on the judgment of the
enrolling physician rather than on prespecified objective
criteria (such as coronary angiography), so some variability
in the classification of etiology may have occurred. In reality,
the development of left ventricular dysfunction is a complex
process in which many potential etiologies may coexist and
contribute to the clinical syndrome of HF in a given patient.
A binary classification system, while attractive due to its
simplicity, is clearly an oversimplification of a complex
physiologic process. Additionally, no standardized defini-
tion of ischemic etiology of HF exists, although a classifi-
cation system based on the results of clinical history and
angiography has recently been proposed (29). Indeed, the
terms “ischemic” and “nonischemic” are imprecise because
demonstrable myocardial ischemia (particularly in the sub-
endocardium) may exist in patients with cardiomyopathy
and no obstructive coronary disease (30,31). Our alternative
analyses suggest that the finding of an interaction between
HF etiology and treatment with milrinone is relatively
insensitive to the method used for classification of etiology.
Study limitations. This study is limited by its retrospective
nature, and, as such, should be considered hypothesis-
generating rather than definitive. Data were not collected on
the level of care that patients received (i.e., intensive care
unit vs. monitored bed), which potentially could have
affected the results of our study, particularly with regard to
the recognition and treatment of arrhythmias. Because the
reasons for rehospitalization are frequently multifactorial in
HF patients, we did not attempt to assign a specific reason
for rehospitalization (i.e., cardiovascular vs. noncardiovas-
cular) in evaluating study end points. Based on the assess-
ment of the site investigator, 93% of all hospital days during
the study period were considered to be due to cardiovascular
causes, suggesting that the impact of noncardiovascular
hospitalizations was low. Finally, although follow-up was
Table 4. Discharge Medications by Heart Failure Etiology and Treatment Assignment
Ischemic Nonischemic
p ValueMilrinone Placebo Milrinone Placebo
Beta-blocker 27% 25% 21% 20% 0.18
ACE inhibitors 74% 74% 75% 76% 0.92
Digoxin 74% 73% 84% 80% 0.02
Amiodarone 20% 18% 19% 16% 0.77
Calcium blocker 14% 10% 16% 11% 0.25
ACE  angiotensin-converting enzyme.
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99% complete for the study, there was an imbalance
between etiologic groups (four patients in the ischemic
group vs. eight patients in the nonischemic group lost to
follow-up), which could potentially have influenced our
conclusions regarding differences in outcomes. This analysis
is strengthened by the standardized ascertainment of base-
line characteristics and outcomes in a large, well-
characterized cohort of patients with exacerbations of HF.
Conclusions. In patients hospitalized for decompensated
HF in the OPTIME-CHF trial, those with nonischemic
HF had a better short- and intermediate-term prognosis
than those with ischemic HF. Intravenous milrinone treat-
ment appeared to have a bidirectional effect in acute HF
based on etiology, with worsened outcomes in those with
ischemic HF and neutral to improved outcomes in those
with nonischemic HF. This finding provides support for the
importance of carefully defining the etiology of HF, which
has important implications not only for prognosis but also
for therapy. Although the specific determination of etiology
for a given patient with HF may be imprecise, our data
suggest that particular caution should be used when con-
templating inotropic therapy in patients with ischemic heart
disease and HF. The morbidity and mortality seen in the
overall OPTIME-CHF study were substantial, with a
mortality rate at 60 days of 9.6% and a rate of death or
rehospitalization at 60 days of 35.2%. This poor short-term
prognosis underscores the need for more research into risk
stratification and optimal treatment strategies for this in-
creasingly prevalent clinical problem.
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